Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
暂无分享,去创建一个
B. Pégourié | P. Moreau | X. Leleu | C. Touzeau | T. Facon | B. Arnulf | M. Attal | B. Royer | J. Fermand | L. Garderet | M. Roussel | A. Stoppa | H. A. Loiseau | D. Caillot | G. Fouquet | M. Chrétien | R. Szalat | A. Caulier | B. Hébraud | L. Benajiba | S. Garciaz | B. Tessoulin | C. Régny
[1] B. Pégourié,et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma , 2013, Leukemia.
[2] M. Kersten,et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Boccadoro,et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. , 2012, Blood.
[4] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[5] M. Beksac,et al. IMWG consensus on maintenance therapy in multiple myeloma. , 2012, Blood.
[6] M. Dimopoulos,et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.
[7] P. Moreau,et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Esseltine,et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. , 2011, Blood.
[9] A. Chanan-Khan,et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Boccadoro,et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Moreau,et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R A Kyle,et al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.
[13] N. Munshi,et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[15] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.